688235:SHA
BeOne Medicines AG
CNÂ¥289.25
arrow_downward
-3.22%(-9.63) 1D
Aug 21, 3:00:01 PM GMT+8 · CNY
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 688235...
Open
CNÂ¥290.04
High
CNÂ¥294.54
Low
CNÂ¥283.80
Mkt. cap
307.41B
Avg. vol.
6.52M
Volume
5.76M
P/E ratio
139.68
52-wk high
CNÂ¥346.00
52-wk low
CNÂ¥205.51
EPS
CNÂ¥2.07
No. of employees
12K
Open
CNÂ¥290.04
High
CNÂ¥294.54
Low
CNÂ¥283.80
Mkt. cap
307.41B
Avg. vol.
6.52M
Volume
5.76M
P/E ratio
139.68
52-wk high
CNÂ¥346.00
52-wk low
CNÂ¥205.51
EPS
CNÂ¥2.07
No. of employees
12K
News stories
From web sources and news partners
Simply Wall Street
·
12 hours ago
BeOne Medicines (ONC) Stock May Be Rich After BRUKINSA Access Renewal
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com
AI content may include mistakes. Learn more